ArticleMolecular and cellular biology2005
B56 regulatory subunit of protein phosphatase 2A mediates valproic acid-induced p300 degradation.
Article in Molecular and cellular biology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 41 citations in OpenAlex.
- Beyond epilepsy: The expanding role of valproic acid in Alzheimer disease therapy - a review.The Journal of pharmacology and experimental therapeutics · 2025Review
- Ubiquitin proteasome system (UPS): a crucial determinant of the epigenetic landscape in cancer.Epigenomics · 2025Review
- p300 nucleocytoplasmic shuttling underlies mTORC1 hyperactivation in Hutchinson-Gilford progeria syndrome.Nature cell biology · 2024Article
- Valproic acid restricts mast cell activation by Listeria monocytogenes.Scientific reports · 2022Article
- Regulation of Dystroglycan Gene Expression in Early Myoblast Differentiation.Frontiers in cell and developmental biology · 2022Article
- Dissecting myogenin-mediated retinoid X receptor signaling in myogenic differentiation.Communications biology · 2020Article
- Loci-specific histone acetylation profiles associated with transcriptional coactivator p300 during early myoblast differentiation.Epigenetics · 2018Article
- Insights into interplay between rexinoid signaling and myogenic regulatory factor-associated chromatin state in myogenic differentiation.Nucleic acids research · 2017Article
- Trichostatin A, a histone deacetylase inhibitor suppresses NADPH Oxidase 4-Derived Redox Signalling and Angiogenesis.Journal of cellular and molecular medicine · 2016Article
- Retinoid X Receptor-selective Signaling in the Regulation of Akt/Protein Kinase B Isoform-specific Expression.The Journal of biological chemistry · 2016Article
- Implication of retinoic acid receptor selective signaling in myogenic differentiation.Scientific reports · 2016Article
- Molecular Basis for the Regulation of Transcriptional Coactivator p300 in Myogenic Differentiation.Scientific reports · 2015Article
- Regulation of histone modifying enzymes by the ubiquitin-proteasome system.Biochimica et biophysica acta · 2014Review
- Activation of GATA4 gene expression at the early stage of cardiac specification.Frontiers in chemistry · 2014Article
- B56γ tumor-associated mutations provide new mechanisms for B56γ-PP2A tumor suppressor activity.Molecular cancer research : MCR · 2013Article
- Induction of Pax3 gene expression impedes cardiac differentiation.Scientific reports · 2013Article
- Stepwise acetyltransferase association and histone acetylation at the Myod1 locus during myogenic differentiation.Scientific reports · 2013Article
- Regulation ofMolecular biology · 2012Article
- Contribution of retinoid X receptor signaling to the specification of skeletal muscle lineage.The Journal of biological chemistry · 2011Article
- Promoter context determines the role of proteasome in ligand-dependent occupancy of retinoic acid responsive elements.Epigenetics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcriptional coactivator p300 is required for embryonic development and cell proliferation. Valproic acid, a histone deacetylase inhibitor, is widely used in the therapy of epilepsy and bipolar disorder. However, it has intrinsic teratogenic activity through unidentified mechanisms. We report that valproic acid stimulates proteasome-dependent p300 degradation through augmentation of gene expression of the B56gamma regulatory subunits of protein phosphatase 2A. The B56gamma3 regulatory and catalytic subunits of protein phosphatase 2A interact with p300. Overexpression of the B56gamma3 subunit leads to proteasome-mediated p300 degradation and represses p300-dependent transcriptional activation, which requires the B56gamma3 interaction domain of p300. Conversely, silencing of the B56gamma subunit expression by RNA interference increases the stability and transcriptional activity of the coactivator. Our study establishes the functional interaction between protein phosphatase 2A and p300 activity and provides direct evidence for signal-dependent control of p300 function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.